Journal of Crohn s and Colitis Impact Factor & Information

Publisher: Oxford University Press (OUP)

Journal description

Current impact factor: 6.23

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 6.234
2013 Impact Factor 3.562
2012 Impact Factor 3.385
2011 Impact Factor 2.566
2010 Impact Factor 2.628
2009 Impact Factor 1.729
2008 Impact Factor 0.812

Impact factor over time

Impact factor

Additional details

5-year impact 5.43
Cited half-life 2.60
Immediacy index 1.42
Eigenfactor 0.01
Article influence 1.27
ISSN 1876-4479
OCLC 196647401
Material type Series, Periodical
Document type Journal / Magazine / Newspaper

Publisher details

Oxford University Press (OUP)

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Conditions
    • Creative Commons Attribution License or Creative Commons Attribution Non-Commercial License available
    • Pre-print on author's personal website, employers website or subject repository
    • Pre-print can only be posted prior to acceptance
    • Pre-print must be accompanied by set statement (see link)
    • Pre-print must not be replaced with post-print, instead a link to published version with amended set statement should be made
    • Publisher's version/PDF must be used
    • Publisher's version/PDF on institutional repository or centrally organised repositories
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany archived copy (see policy)
    • Eligible authors may deposit in OpenDepot
    • Publisher will deposit on behalf of NIH, HHMI, UK MRC, Telethon and Wellcome Trust funded authors to PubMed Central and Europe PMC
    • All titles are open access journals
    • This policy is an exception to the default policies of 'Oxford University Press (OUP)'
  • Classification
    ​ green

Publications in this journal

  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv177
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv172
  • [Show abstract] [Hide abstract]
    ABSTRACT: DURING ACTIVE INFLAMMATORY BOWEL DISEASE IBD: fatigue is a common symptom, which seems related to active gut inflammation. However, even in remission, many patients suffer from fatigue that negatively affects quality of life and work productivity. Currently, robust knowledge on the pathogenesis and treatment of IBD-related fatigue is lacking. In order to alleviate the burden of IBD-related fatigue, a systematic approach is mandatory. We propose a fatigue attention cycle to enhance identification, evaluation and management of fatigued IBD patients. The benefits of the cycle are twofold. Firstly, it allows for systematic and uniform identification of patients with severe fatigue, in turn allowing for tailored non-pharmacological and pharmacological interventions. Secondly, uniform identification of such patients creates a well-defined patient base to investigate the underlying pathogenesis of fatigue, resulting in a greater understanding of this debilitating phenomenon and possibly resulting in the discovery of predictive factors and new treatment interventions.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv168
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim: of this study was to estimate the short and long-term efficacy and safety of ADA in UC patients from each Hungarian biological center. Patients and methods: This prospective study consisted of UC patients treated with ADA in 10 Hungarian IBD centers. The primary endpoints of the study were rates of continuous clinical response, remission, non-response and loss of response at weeks 12, 30 and 52.The secondary endpoints included mucosal healing at week 52 and the compare of the efficacy of ADA between biological naive and IFX-treated group. Colonoscopy was performed before starting the therapy and at week 52. Results: Seventy-three active UC patients were enrolled in the study. 67.1% of the patients received previous IFX therapy. 75.3% of the patients showed short-term clinical response at week 12. The probability of maintaining ADA was 48.6% at week 52 with a continuous clinical response in 92% of these remaining patients. Mucosal healing was achieved in 48.1% of the patients at week 52. Escalation of ADA was performed in 17.6%, minor side effects developed in 4% of the patients. 5.4% of the patients underwent colectomy during the oneyear treatment period. Discussion: UC is a progressive disease that may need an early aggressive therapy to prevent the structural and functional complications. The results of our study demonstrated the favorable efficacy of short and long-term ADA treatment for patients with UC.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv169
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Small bowel capsule endoscopy (SBCE) allows mapping of small-bowel (SB) inflammation in Crohn's disease (CD). We aim to assess the prognostic value of the severity of inflammatory lesions, quantified by the Lewis Score (LS), in patients with isolated SB CD. Methods: Retrospective study, including 53 patients with isolated SB CD, submitted to SBCE at the time of diagnosis. LS was calculated and patients had at least 12 months of follow-up post-diagnosis. As adverse events we defined disease flare requiring systemic corticosteroid therapy, hospitalization and/or surgery during follow-up. We compared the incidence of adverse events in 2 patients subgroups i.e. those with moderate or severe inflammatory activity (LS≥790) vs those with mild inflammatory activity (135≤LS<790). Results: LS was ≥790 in 22 patients (41,5%), while 58,5% presented with LS between 135 and 790. Patients with higher LS were more frequently smokers (p=0,01), males (p=0,017) and were more frequently under immunosuppressive therapy (p=0,004). In multivariate analysis moderate to severe disease at SBCE was independently associated to corticosteroid therapy during follow-up with a RR of 5 (p=0.011; 95% CI 1.5-17.8) and for hospitalization with a RR of 13.7 (p=0.028; 95%CI 1.3-141.9). Conclusion: In patients with moderate to severe inflammatory activity there was a higher prevalence of corticosteroid therapy demand and hospitalizations during follow-up. Thus, stratifying the degree of SB inflammatory activity with SBCE and LS calculation at the time of diagnosis provided relevant prognostic value in patients with isolated SB CD.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv166
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims: In western countries, tuberculous anal fistula may not be an issue because tuberculosis (TB) is not common and it is a very rare form of extrapulmonary manifestation of TB. However in TB-endemic countries, careful diagnostic differentiation is required because the clinical features of TB anal fistula and Crohn's anal fistula (CD) are similar, with distinguishing features remaining unclear. We aimed to analyze the clinical features of TB versus CD anal fistulas. Method: Among 13,872 patients who underwent anal fistula surgery from 2003 to 2014, 87 patients with TB fistulas and 116 patients with CD fistulas were included. Data on the annual incidence of TB and CD, as well as the clinical, pathological, ultrasonographic, colonoscopic and surgical data were analyzed. Results: Compared with CD, the TB group was older (median: 37 vs. 22 years) and underlying chronic illness was more common (20.3% vs. 2.6%). In the TB group, 46 patients (59.7%) showed active or inactive pulmonary TB, and acid-fast bacilli and caseating granuloma was found in 56.3% and 62.1%, respectively. During colonoscopy, mucosal lesions were observed more frequently in CD (96.9% vs. 16.9%). Conclusions: TB anal fistula is clinically very similar to CD anal fistula. In Korea, the incidence of CD anal fistula has recently increased in prevalence, while the prevalence of TB anal fistula is decreasing but is still persistent. We recommend that clinicians should prepare for a possibility of TB as well as CD anal fistula in TB-endemic countries including Korea.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv164
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and AimsEstimating health-related utility weights in Crohn's Disease (CD) patients is crucial for assessing the cost-effectiveness of new pharmaceutical interventions. Values used in most analyses are based on secondary data and vary substantially among studies. We estimated utility weights in a consecutive sample of real-world CD patients.Methods Patients enrolled in an ongoing socio-economic study of CD in the Israeli adult patient population completed a self-administered SF-36 and SIBDQ questionnaires and were assessed for their current clinical status, including the Harvey-Bradshaw Index (HBI) of disease severity. For each patient enrolled we calculated a utility weight using the SF-6D scoring system.ResultsThe cohort comprised of 425 patients: (40% male), with mean age of 39.1 (±14.0) years. The average HBI was 6.1 (± 5.4); 198 (47%) patients were in remission state (HBI<5), 99 (23%) had mild disease (HBI 5-7), 102 (25%) moderate (HBI 8-16) and 26 (6%) severe disease (HBI>16). Mean utility weights were:0.667 in all patients, 0.744 in patients with disease remission, 0.638 in mild disease, 0.587 in moderate disease, and 0.505 in severe disease. The significant predictors of utility weights in a multivariable regression analysis were the HBI (β= -0.494; p<0.001), economic status (β=0.198; p<0.001), time since diagnosis (β=0.106; p<0.001), male (compared with female) gender (β=0.099; p=0.009), hospital admission in the last year for any cause (β=-0.086; p=0.027), and treatment with steroids (β=-0.100; p=0.012) where β denotes the standardized regression coefficients; Model Adjusted R(2)=0.428.Conclusions Utility weights for patients in the remission and mild disease states were generally lower as compared to values used in published cost-effectiveness analyses. These values should be considered when assessing the value for money of future interventions for CD.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv167
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv157
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv165
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv163
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv154
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present the case of a Herpes simplex virus-1 (HSV-1) sepsis with severe herpes hepatitis in a young female treated with triple immunosuppressive therapy (adalimumab, azathioprine, prednisolone) for refractory Crohn's disease (CD). The patient presented with high fever, generalized abdominal tenderness, strongly elevated transaminases, coagulopathy, and pancytopenia. Comprehensive diagnostics including blood HSV-1 PCR, liver biopsy, and immunohistochemistry revealed the diagnosis of fulminant herpes hepatitis. HSV-1 positivity of cutaneous lesions proved the disseminated nature of the infection. Early treatment with intravenous acyclovir led to a rapid improvement of the patients' condition and resulted in a full recovery of her liver function. This is the first reported case of HSV-sepsis in a patient with CD. Physicians treating IBD patients with combined immunosuppressive therapy should be aware of the possibility of herpes hepatitis, and early empiric antiviral therapy should be considered in immunosuppressed patients presenting with fever and severe anicteric hepatitis.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv149
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Mucosal healing in ulcerative colitis (UC) has become a common endpoint in most clinical trials and a relevant therapeutic goal in clinical practice. Despite important differences between endoscopic Mayo scores 0 and 1, both of them are considered as mucosal healing in most important trials. Aim of the present study was to evaluate the risk of relapse in UC patients according to the degree of mucosal healing (endoscopic Mayo scores of 0 and 1). Methods: A prospective longitudinal cohort study was designed. All UC patients who presented with mucosal healing at colonoscopy were consecutively included. Mucosal healing was defined as an endoscopic Mayo score of 0 or 1. Clinical relapse was defined as the need for therapy to induce remission, for any treatment escalation, hospitalization or colectomy. All clinical relapses were evaluated at months 6 and 12 from study entry. Results are analyzed by unconditional stepwise logistic and Kaplan-Meier regressionanalysis. Results: 187 consecutive UC patients [126 (67.3%) Mayo-0 and 61 (32.7%) Mayo-1] were included. 9.4% of patients with Mayo-0 and 36.6% with Mayo-1 presented a relapse during the first 6 months of follow-up (p<0.001). The only factor independently associated with UC relapses in the multivariate analysis was an endoscopic Mayoscore of 1 (OR=6.27, 95%CI 2.73-14.40, p<0.001). Conclusions: Patients with an endoscopic Mayo score of 1 have a higher risk of relapse than those with a Mayo score of 0. The concept of mucosal healing should be limited to patients with an endoscopic Mayo score of 0.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv158
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims: Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults. Methods: A multicenter prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine for years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres assessed before, 3 weeks and 6 months post-vaccination. Results: At inclusion, 31 patients had no IS (Group A), 77 IS without anti-TNF (Group B) and 117 anti-TNF with or without IS (Group C). Three weeks after the first vaccination, rates of seroprotection were 77%, 75% and 66% for A/H1N12007 strain (p=0.35), 77%, 68% and 52% for A/H3N2 strain (p=0.014) and 97%, 96% and 95% for B strain (p=0.99) in groups A, B, and C, respectively. Seroconversion rates for A/H1N12007 strain (67%, 64%, 54%; p=0.28), A/H3N2 strain (63%, 50%, 41%; p=0.074) and B strain (63%, 76%, 60%; p=0.078) were not significantly different according to treatment group. At 6 months after vaccination, seroprotection rates were lower in Group C compared to Group A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores has been detectedConclusions:Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with, Number NCT01022749.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv152
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Increasing evidence suggests that keratoconus may have an inflammatory component. The possible association of keratoconus with inflammatory bowel disease has yet to be determined. The aim of this study is to determine the prevalence of keratoconus and keratoconus suspect in patients with inflammatory bowel disease. Methods: All consecutive adult IBD patients seen in the Department of Gastroenterology (Nancy, University Hospital, France) between March 2014 and June 2014 were included. Pregnant women, rigid lens wearers, patients with family history of keratoconus, and patients with a history of refractive surgery were excluded from the study. A control group of healthy subjects was included. All of the included patients underwent a corneal topography (OPD scan III, Nidek) to detect keratoconus or keratoconus suspect. Rabinowitz videokeratographic indices were the basis of corneal topography interpretation. Results: Two hundred and one inflammatory bowel disease patients were included, 150 with Crohn's disease and 51 with ulcerative colitis. Mean age was 38.7, 121 were women. Mean disease duration was 10.8 years. Two IBD patients were diagnosed with keratoconus (1%) and 38 with keratoconus suspect (18.9%). Overall prevalence of keratoconus and keratoconus suspect was 19.9% (95% confidence interval (CI) (17.5-22.0). None of the 100 healthy subjects had keratoconus, while three were diagnosed with keratoconus suspect (p=0.0002 versus inflammatory bowel disease patients). Only smoking was identified as a risk factor (p=0.029), especially in Crohn's disease. Conclusion: Inflammatory bowel disease patients may carry an increased risk of keratoconus and keratoconus suspect, smoking further increasing this risk. This supports the hypothesis of an inflammatory origin of keratoconus.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv151
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv143
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv146
  • Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv155
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and aimsFecal calprotectin (fcal) is a biomarker of Crohn's disease (CD) endoscopic activity. Identifying the endoscopic situations in which fcal is less reliable remains unexplored. We aimed to determine the endoscopic factors influencing fcal level in CD.Methods Overall, 53 CD patients underwent consecutively and prospectively colonoscopy, with CD Endoscopic Index of Severity (CDEIS) calculation and stool collection. Fcal was measured using quantitative immunochromatographic test. Correlation analysis was done with Pearson statistics.ResultsFcal was correlated with CDEIS (0.66, p<0.001). In univariate analysis, fcal was correlated with the affected surface (0.65, p<0.001) and the ulcerated surface (0.47, p<0.001). Fcal was significantly associated with ulcerations depth, with median fcal of 867.5µg/g, 1251.0µg/g and 1800.0µg/g, in patients presenting with non-ulcerated lesions, superficial ulcerations (SU) and deep ulcerations (DU), respectively. Lesions locations did not influence fcal. In multivariate analysis, fcal was associated with affected surface (p=0.04) and the presence of CD lesions. Moreover, fcal increased with the ulcerations depth (p=0.03). However, ulcerated surface and CD location did not impact fcal. Using a ROC curve, we showed that fcal of 400µg/g was the best compromise between sensitivity (0.76) and specificity (0.77) while fcal ≥200µg/g was highly sensitive (0.86) to detect SU or DU.Conclusions Fcal is a very reliable biomarker to detect endoscopic ulcerations in CD. We suggest repeating measurement in case of intermediary results (200-400µg/g) in daily practice. Fcal level is mostly influenced by the presence of CD lesions (even non-ulcerated), in a depth-related manner and by the affected surface.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv150
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Anti-TNF agents have dramatically improved the prognosis of inflammatory bowel disease (IBD). However, despite their good safety profile these agents may lead to paradoxical manifestations involving skin or joints. Pathogenesis of such side effects is poorly understood and may involve anti-TNF pharmacokinetics. Aim: The aim of the present study was to look for an association between infliximab trough levels (ITL) and cutaneous (CPM) or rheumatologic (RPM) paradoxical manifestations. Methods: IBD patients receiving infliximab as maintenance therapy were included in a transversal prospective monocenter study. At inclusion, patients had an ITL measurement (LISA-TRAKER®, Biomedical Diagnostics BMD) and were assessed for paradoxical manifestations: CPM was defined by new onset or exacerbation of pre-existing psoriasis lesions during IFX therapy and RPM by new onset of severe poly-arthralgia during IFX therapy. Results: Among the 121 patients included (69 female; median age: 38.9 years; 92 with Crohn's disease), 7% had CPM and 8% RPM. Median ITL values were 5.87 (range: 0.52-19.53) µg/mL in patients with CPM and 1.90 (0.00-13.5) µg/mL in those with RPM, as compared respectively to 5.12 (0.00-49.12) µg/mL in patients without CPM (p=0.56) and 5.57 (0.00-49.12) µg/mL in those without RPM (p=0.058). No prognostic factor was associated with CPM. The single factor associated with RPM was elevated anti-nuclear antibodies. Conclusion: ITL were not elevated in IBD patients developing cutaneous or rheumatologic paradoxical manifestations when receiving IFX as maintenance therapy. As suggested by high level of antinuclear antibodies, RPM could be related to an induced autoimmune disorder.
    Journal of Crohn s and Colitis 09/2015; DOI:10.1093/ecco-jcc/jjv159